Amgen Inc.
INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) BINDING PROTEINS AND METHODS OF USE

Last updated:

Abstract:

The present disclosure provides a method of improvement, preservation, prophylaxis, or inhibition-of-deterioration of a healthspan parameter of a mammalian subject. In exemplary embodiments, the method comprises administering to the subject a composition that comprises an insulin-like growth factor-1 receptor (IGF-1 R) inhibitor, wherein the composition is administered in an amount effective to improve, provide prophylaxis for, or inhibit-the-deterioration of the healthspan parameter.

Status:
Application
Type:

Utility

Filling date:

30 Aug 2018

Issue date:

28 Oct 2021